CoChat

Cardiovascular effects of GLP‐1 and GLP‐1‐based therapies: implications for the cardiovascular continuum in diabetes?

Burgmaier, M., Heinrich, C., Marx, N. · 2013 · Diabetic Medicine
Cited by 40

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Diabet. Med. 30, 289–299 (2013) Aims Glucagon‐like peptide‐1 receptor agonists and inhibitors of dipeptidyl peptidase‐4 that increase glucagon‐like peptide‐1 plasma concentrations are current treatment options for patients with diabetes mellitus. As patients with diabetes are a high‐risk population for the development of a severe and diffuse atherosclerosis, we aim to review the potential action of these drugs on cardiovascular disease and to summarize the potential role of present glucagon‐like peptide‐1‐based therapies from a cardiologist’s point of view. Methods Using a PubMed/MEDLINE search without language restriction, studies were identified and evaluated in order to review the effects of glucagon‐like peptide‐1‐based therapy on different stages of the cardiovascular continuum. Results Recent experimental as well as clinical data suggest that dipeptidyl peptidase‐4 inhibitors and glucagon‐like peptide‐1 receptor agonists—in addition to their metabolic effects—may have beneficial effects on the cardiovascular continuum at multiple stages, including: (1) cardiovascular risk factors; (2) molecular mechanisms involved in atherogenesis; (3) ischaemic heart disease; and (4) heart failure. Furthermore, retrospective analysis suggested decreased cardiovascular events in patients with glucagon‐like peptide‐1‐based therapies. Conclusion There are ample data to suggest beneficial effects of glucagon‐like peptide‐1‐based therapies on the cardiovascular continuum and large‐scale clinical trials are warranted to determine whether these effects translate into improved cardiovascular endpoints in humans.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2012.03746.x

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 40

Metadata

Authors
Burgmaier, M., Heinrich, C., & Marx, N.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2013-02-20
Volume
30
Issue
3
Pages
289-299
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W1514615788
Cited by
40
References
15
FWCI
5.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiovascular effects of GLP‐1 and GLP‐1‐based therapies: implications for the cardiovascular continuum in diabetes? https://app.cochat.ai/papers/10.1111/j.1464-5491.2012.03746.x
The paper
Burgmaier, M., Heinrich, C., & Marx, N. (2013). Cardiovascular effects of GLP‐1 and GLP‐1‐based therapies: implications for the cardiovascular continuum in diabetes? Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2012.03746.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.